For example, the BCL-2 inhibitor peptidomimetics ABT-199 (Venetoclax) is presently used in clinical trials in certain lymphomas, leukemia, or multiple myeloma (reviewed by Ashkenazi et al. [99]). This evidence concerns the gene BCL2 and leukemia.